The REMIT-DAPA trial found that individuals with T2DM and comorbid heart failure who received a regimen of insulin, dapagliflozin, and metformin had a 2-year remission rate of 38.7%, compared to 21.5% in those treated with insulin and metformin. This evidence concerns the gene INS and heart failure.